Ekso Bionics (NASDAQ:EKSO) will post its quarterly earnings results after the market closes on Thursday, August 1st.
Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Wednesday, May 1st. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). The business had revenue of $3.62 million during the quarter, compared to analysts’ expectations of $3.98 million. Ekso Bionics had a negative return on equity of 501.28% and a negative net margin of 206.32%.
Shares of NASDAQ:EKSO traded down $0.01 during midday trading on Tuesday, reaching $1.17. The company’s stock had a trading volume of 7,282 shares, compared to its average volume of 252,934. The business has a 50 day moving average of $1.26. The stock has a market capitalization of $86.06 million, a price-to-earnings ratio of -2.66 and a beta of 1.45. The company has a quick ratio of 1.39, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Ekso Bionics has a 12-month low of $1.12 and a 12-month high of $3.30.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Read More: How is the LIBOR rate calculated?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.